Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialResearch in context

Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialResearch in context

Summary: Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit. Methods: The phase 3 PANTHER trial (NCT00798070) compared adjuvant sequential epirubicin/cyclophosphamide (EC) and docetaxel...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexios Matikas, Andri Papakonstantinou, Sibylle Loibl, Günther G. Steger, Michael Untch, Hemming Johansson, Nikos Tsiknakis, Mats Hellström, Richard Greil, Volker Möbus, Michael Gnant, Jonas Bergh, Theodoros Foukakis
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:The Lancet Regional Health. Europe
Subjects:
Adjuvant chemotherapy
Amenorrhea
Breast cancer
Dose-dense
PREDICT
STEPP
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776224003314
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666776224003314

Similar Items